Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Al Ali, Najla [1 ]
Sallman, David [1 ]
Chan, Onyee [1 ]
Padron, Eric [1 ]
Sweet, Kendra [1 ]
Kuykendall, Andrew [1 ]
Lancet, Jeffrey [1 ]
Komrokji, Rami [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
MDS; azacitidine; venetoclax;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-128
引用
收藏
页码：S341 / S341
页数：1
相关论文
共 50 条
  • [21] Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
    Wang, Xin
    Xiao, Zhijian
    Qin, Tiejun
    Xu, Zefeng
    Jia, Yujiao
    Qu, Shiqiang
    Li, Bing
    Pan, Lijuan
    Gao, Qingyan
    Jiao, Meng
    Gale, Robert Peter
    [J]. HEMATOLOGY, 2024, 29 (01)
  • [22] Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
    Zeidan, Amer M.
    Gore, Steven D.
    Komrokji, Rami S.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (03) : 251 - 254
  • [23] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2008, 112 (11) : 88 - 89
  • [24] A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome
    Wei, Andrew H.
    Garcia, Jacqueline S.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Peterlin, Pierre
    Jurcic, Joseph G.
    Garcia-Manero, Guillermo
    Hong, Wan-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Dunbar, Martin
    Zhou, Ying
    Harb, Jason
    Tanwani, Poonam
    Wolff, Johannes E.
    Jacoby, Meagan
    [J]. BLOOD, 2019, 134
  • [25] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
    Chen, James
    Johnson, Lisa
    McKenna, Kelly
    Choi, Timothy
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
  • [26] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    [J]. BLOOD, 2008, 112 (11) : 91 - 91
  • [27] Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naive higher-risk myelodysplastic syndromes.
    Zeidan, Amer Methqal
    Garcia, Jacqueline Suen
    Fenaux, Pierre
    Platzbecker, Uwe
    Miyazaki, Yasushi
    Xiao, Zhi-Jian
    Zhou, Ying
    Naqvi, Kiran
    Kye, Steve
    Garcia-Manero, Guillermo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world
    高清妍
    [J]. China Medical Abstracts(Internal Medicine)., 2024, 41 (03)
  • [29] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Kishtagari, Ashwin
    Sanikommu, Srinivasa R.
    Al-Kali, Aref
    Lee, Je-Hwan
    Burgues, Juan M. Bergua
    Diez-Campelo, Maria
    Erba, Harry P.
    Garcia-Hernandez, Carmen
    Santillana, Guillermo Sanz
    O'Connell, Casey
    Jang, Jun-Ho
    Shin, Dong-Yeop
    Sayar, Hamid
    Rao, Mayank
    Schwartz, Richard S.
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Tsiatis, Athanasios C.
    Altman, Jessica K.
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [30] Overview of the Management of Higher-Risk Myelodysplastic Syndromes
    Singh, Abhay
    Carraway, Hetty E.
    [J]. CANCER JOURNAL, 2023, 29 (03): : 160 - 167
12345